Frontline BV+CHP and Brentuximab Vedotin Maintenance in CD30-Positive Peripheral T-Cell Lymphoma: A Real-World Study

Background/Objectives: We describe frontline brentuximab vedotin (BV) combined with cyclophosphamide, doxorubicin and prednisone (BV+CHP) and subsequent treatment in adults with CD30-positive peripheral T-cell lymphoma (PTCL). Methods: This single-center retrospective cohort included 18 adults treated with BV+CHP. We assessed end-of-induction response in the full cohort and recorded the first post-transplant response separately among recipients of autologous stem cell transplantation (ASCT). Overall survival (OS) and progression-free survival (PFS) were estimated from the first BV+CHP dose. Results: At the end of BV+CHP induction, before ASCT or BV maintenance where applicable, 15 of 18 patients achieved complete response (CR, 83.3%, 95% CI 58.6–96.4%). Three patients progressed during induction. Ten patients entered ASCT in first CR, and all remained in CR at the first post-ASCT assessment (median 62.5 days, range 55–70). Eight patients received BV maintenance, including five after ASCT. Three of the eight subsequently progressed and died. Median potential follow-up was 39.5 months by reverse Kaplan–Meier. The 24-month OS and PFS estimates were both 66.7% (95% CI 40.4–83.4%). Conclusions: The study describes outcomes after frontline BV+CHP in a small, histologically heterogeneous cohort. A comparative study is needed to determine whether BV maintenance affects relapse or survival.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-18
DOI
https://doi.org/10.3390/jcm15229027
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Frontline BV+CHP and Brentuximab Vedotin Maintenance in CD30-Positive Peripheral T-Cell Lymphoma: A Real-World Study

Sinem Namdaroğlu, Semih Başçı, Eray Arslan, Hikmetullah Batgi et al.
1 links
Journal of Clinical Medicine
Lymphoma Diagnosis and Treatment
article

Frontline BV+CHP and Brentuximab Vedotin Maintenance in CD30-Positive Peripheral T-Cell Lymphoma: A Real-World Study

Sinem Namdaroğlu, Semih Başçı, Eray Arslan, Hikmetullah Batgi, Berna Güzel, Kardelen Tayfur
article en

Abstract

Background/Objectives: We describe frontline brentuximab vedotin (BV) combined with cyclophosphamide, doxorubicin and prednisone (BV+CHP) and subsequent treatment in adults with CD30-positive peripheral T-cell lymphoma (PTCL). Methods: This single-center retrospective cohort included 18 adults treated with BV+CHP. We assessed end-of-induction response in the full cohort and recorded the first post-transplant response separately among recipients of autologous stem cell transplantation (ASCT). Overall survival (OS) and progression-free survival (PFS) were estimated from the first BV+CHP dose. Results: At the end of BV+CHP induction, before ASCT or BV maintenance where applicable, 15 of 18 patients achieved complete response (CR, 83.3%, 95% CI 58.6–96.4%). Three patients progressed during induction. Ten patients entered ASCT in first CR, and all remained in CR at the first post-ASCT assessment (median 62.5 days, range 55–70). Eight patients received BV maintenance, including five after ASCT. Three of the eight subsequently progressed and died. Median potential follow-up was 39.5 months by reverse Kaplan–Meier. The 24-month OS and PFS estimates were both 66.7% (95% CI 40.4–83.4%). Conclusions: The study describes outcomes after frontline BV+CHP in a small, histologically heterogeneous cohort. A comparative study is needed to determine whether BV maintenance affects relapse or survival.

Journal of Clinical MedicineVol. 15(22)
Dokuz Eylül University (TR)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon